- Conditions
- Type 2 Diabetes, High Blood Pressure
- Interventions
- Polypill, Combined prescription of the individual medications
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Dallas, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 32
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Crohn's Disease, Glycogen Metabolism, Inflammatory Bowel Disease (IBD)
- Interventions
- Empagliflozin
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Heart Failure
- Interventions
- Polypill, Control Rx
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 212 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Obesity, Weight Loss
- Interventions
- Empagliflozin Arm, Control Arm, Exercise capacity VO2 maximum determination, Exercise Challenge
- Drug · Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 80 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Diabetes Mellitus, Type 2, Hyperglycemia
- Interventions
- Metformin 500 mg bid, Metformin 1000 mg bid, Empagliflozin low dose qd, Empagliflozin high dose qd, Empagliflozin low dose bid, Empagliflozin high dose bid
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,413 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Manley Hot Springs, Alaska • Glendale, Arizona + 33 more
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- Empagliflozin + Potassium Chloride, Empagliflozin + Potassium Nitrate, Potassium Chloride + Placebo for Empagliflozin
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Placebo identical to BI 10773 high dose, Placebo identical to BI 10773 low dose, BI 10773
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,504 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Tempe, Arizona • Huntington Park, California + 21 more
- Conditions
- Diabetes Mellitus and Heart Failure
- Interventions
- LIK066, Placebo, Empagliflozin
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 21
- States / cities
- Huntsville, Alabama • Carmichael, California • Concord, California + 18 more
- Conditions
- Gout and Hyperuricemia
- Interventions
- Empagliflozin 10 mg, Placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Non-Alcoholic Fatty Liver Disease
- Interventions
- Empagliflozin 10 MG, Placebo Oral Tablet
- Drug
- Lead sponsor
- Justin Ryder
- Other
- Eligibility
- 16 Years to 20 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Thrombosis
- Interventions
- Sotagliflozin, Empagliflozin
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Obesity, Metabolic Syndrome
- Interventions
- Empagliflozin 25 MG, Placebo
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Epilepsy
- Interventions
- Empagliflozin 25 mg, Placebo
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Liver Cirrhosis, Cirrhosis, Ascites, Ascites Hepatic, Sodium-Glucose Transporter 2 Inhibitors
- Interventions
- Empagliflozin 10 MG
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Redwood City, California
- Conditions
- Adult Congenital Heart Disease, Heart Failure
- Interventions
- Empagliflozin 10 MG, Placebo
- Drug
- Lead sponsor
- Anita Saraf
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 3
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Dulaglutide, Placebo, SGLT2 inhibitor, Metformin
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 424 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 13
- States / cities
- Encino, California • Huntington Park, California • Los Angeles, California + 9 more
- Conditions
- Prediabetes
- Interventions
- Empagliflozin 10mg daily, Lifestyle education
- Drug · Other
- Lead sponsor
- Charles George VA Medical Center
- Federal
- Eligibility
- 35 Years to 60 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Asheville, North Carolina
- Conditions
- Covid19
- Interventions
- theraputic heparin, prophylactic heparin, P2Y12, Crizanlizumab Injection, SGLT2 inhibitor
- Drug
- Lead sponsor
- Matthew Neal MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3,591 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 81
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 65 more
- Conditions
- Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases
- Interventions
- Vicadrostat, Empagliflozin, Placebo matching Vicadrostat
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11,800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 210
- States / cities
- Anniston, Alabama • Fairhope, Alabama • Guntersville, Alabama + 173 more
- Conditions
- Type 2 Diabetes Mellitus, Chronic Kidney Disease
- Interventions
- Finerenone (BAY94-8862 ) 10 mg, Empagliflozin, Empagliflozin Placebo, Finerenone (BAY94-8862 ) 20 mg, Finerenone Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,664 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 46
- States / cities
- Surprise, Arizona • Los Angeles, California • Northridge, California + 36 more
- Conditions
- HER2-positive Breast Cancer, HER2+ Breast Cancer
- Interventions
- Carvedilol, Empagliflozin
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Empaglifozin, Physiological Effects of Drugs, Hypoglycemic Agents, Sodium-Glucose Transporter 2 Inhibitors
- Interventions
- empagliflozin (Jardiance) 25 mg
- Drug
- Lead sponsor
- National Institute on Aging (NIA)
- NIH
- Eligibility
- 55 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Kidney Failure, Chronic, Heart Failure
- Interventions
- Empagliflozin 25 mg thrice-weekly post-hemodialysis dosing, Empagliflozin 10 mg daily dosing
- Drug
- Lead sponsor
- University of Mississippi Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 2
- States / cities
- Jackson, Mississippi
- Conditions
- Patients
- Interventions
- Empagliflozin, Dorzagliatin
- Drug
- Lead sponsor
- Hua Medicine Limited
- Industry
- Eligibility
- 30 Years to 65 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Hackensack, New Jersey